Addex Therapeutics (ADXN.SW) Validates Potential Efficacy Biomarker for Phase 1 Trial of Its GABA-B Positive Allosteric Modulator, ADX71441
5/21/2013 11:13:51 AM
More...
|
Addex Therapeutics (ADXN.SW) Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human Primate PET Study
5/1/2013 11:52:38 AM
More...
|
Addex Therapeutics (ADXN.SW) Announces CFO, Tim Dyer, to Transition to External Consulting Role
5/1/2013 11:49:01 AM
More...
|
Addex Therapeutics (ADXN.SW) Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence
4/30/2013 11:11:15 AM
More...
|
Addex Therapeutics (ADXN.SW) Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant
4/22/2013 12:10:23 PM
More...
|
Addex Therapeutics (ADXN.SW) Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1)
4/18/2013 11:12:05 AM
More...
|
Addex Therapeutics (ADXN.SW) Receives Approval to Initiate a Phase 1, First-In-Man, Clinical Study for ADX71441
3/27/2013 6:50:17 AM
More...
|
Addex Therapeutics (ADXN.SW) Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology
3/22/2013 8:50:49 AM
More...
|
Addex Therapeutics (ADXN.SW) Shareholders Approve All Board Proposals at Annual General Meeting
3/20/2013 9:09:44 AM
More...
|
Addex Therapeutics (ADXN.SW) Awarded $1 Million Grant From The Michael J. Fox Foundation for Parkinson's Research
3/19/2013 9:04:41 AM
More...
|
|